Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus cisplatin/gemcitabine versus placebo plus cisplatin/gemcitabine in first-line advanced non-squamous non-small cell lung cancer
2004-000864-29Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Bevacizumab + cisplatin + gemcitabine with Placebo + cisplatin + gemcitabine (2 arms). Primary endpoint: Progression-free survival. Started Sep 2004; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-000864-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000864-29.